MSAM
NVO

Moloney Securities Asset Management’s Novo Nordisk NVO Stock Holding History

Moloney Securities Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.32M Buy
23,699
+12,530
+112% +$733K 0.16% 156
2025
Q2 		$771K Sell
11,169
-6,289
-36% -$428K 0.1% 213
2025
Q1 		$1.21M Buy
17,458
+7,661
+78% +$633K 0.16% 151
2024
Q4 		$843K Sell
9,797
-1,011
-9% -$109K 0.11% 200
2024
Q3 		$1.29M Sell
10,808
-4,103
-28% -$547K 0.17% 140
2024
Q2 		$2.13M Buy
14,911
+1,970
+15% +$261K 0.31% 78
2024
Q1 		$1.66M Buy
12,941
+827
+7% +$98.4K 0.25% 98
2023
Q4 		$1.25M Sell
12,114
-50
-0.4% -$4.95K 0.2% 128
2023
Q3 		$1.11M Sell
12,164
-600
-5% -$52.9K 0.2% 123
2023
Q2 		$1.03M Buy
12,764
+102
+0.8% +$8.33K 0.18% 136
2023
Q1 		$1.01M Sell
12,662
-2,254
-15% -$160K 0.19% 141
2022
Q4 		$1.01M Sell
14,916
-346
-2% -$20.3K 0.22% 127
2022
Q3 		$760K Sell
15,262
-2,100
-12% -$112K 0.18% 145
2022
Q2 		$967K Sell
17,362
-400
-2% -$22.2K 0.23% 127
2022
Q1 		$986K Buy
17,762
+262
+1% +$13.4K 0.19% 140
2021
Q4 		$980K Sell
17,500
-400
-2% -$21.7K 0.17% 150
2021
Q3 		$859K Sell
17,900
-3,300
-16% -$160K 0.16% 175
2021
Q2 		$888K Hold
21,200
– – 0.16% 158
2021
Q1 		$715K Sell
21,200
-200
-0.9% -$7.12K 0.14% 170
2020
Q4 		$747K Sell
21,400
-480
-2% -$16.6K 0.17% 154
2020
Q3 		$760K Hold
21,880
– – 0.2% 129
2020
Q2 		$716K Sell
21,880
-670
-3% -$21.4K 0.21% 121
2020
Q1 		$679K Sell
22,550
-400
-2% -$11.9K 0.24% 111
2019
Q4 		$664K Hold
22,950
– – 0.21% 136
2019
Q3 		$593K Sell
22,950
-546
-2% -$13.8K 0.2% 134
2019
Q2 		$600K Buy
23,496
+662
+3% +$16.4K 0.2% 136
2019
Q1 		$597K Sell
22,834
-2,662
-10% -$65.4K 0.21% 138
2018
Q4 		$587K Hold
25,496
– – 0.24% 120
2018
Q3 		$601K Buy
25,496
+200
+0.8% +$4.88K 0.21% 131
2018
Q2 		$583K Sell
25,296
-4,300
-15% -$102K 0.22% 137
2018
Q1 		$729K Sell
29,596
-2,800
-9% -$73.5K 0.3% 112
2017
Q4 		$869K Sell
32,396
-4,800
-13% -$122K 0.37% 93
2017
Q3 		$895K Sell
37,196
-1,354
-4% -$30.6K 0.4% 75
2017
Q2 		$827K Buy
38,550
+2,000
+5% +$40.4K 0.41% 71
2017
Q1 		$626K Sell
36,550
-18,756
-34% -$327K 0.32% 97
2016
Q4 		$992K Buy
+55,306
New +$1M 0.6% 41

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Moloney Securities Asset Management's NVO Position: Q3 2025 in Review

Moloney Securities Asset Management increased its Novo Nordisk (NVO) stake by 112% in Q3 2025, buying an estimated $733K and bringing the position to 23,699 shares worth $1.32M. The position accounts for 0.16% of the portfolio, ranked #156.

Moloney Securities Asset Management first reported a position in NVO in Q4 2016 and has held it in 36 quarters since. The position peaked at $2.13M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Moloney Securities Asset Management held 23,699 shares of Novo Nordisk worth $1.32M as of Q3 2025.
  • Moloney Securities Asset Management bought 12,530 Novo Nordisk shares in Q3 2025, an estimated $733K.
  • Novo Nordisk made up 0.16% of Moloney Securities Asset Management's portfolio in Q3 2025, its #156 holding.
  • Moloney Securities Asset Management first reported a position in Novo Nordisk in Q4 2016 and has held it in 36 quarters since.
  • Moloney Securities Asset Management's Novo Nordisk position peaked at $2.13M in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.